Champlain Investment Partners LLC decreased its position in shares of Masimo Co. (NASDAQ:MASI) by 0.4% during the 1st quarter, HoldingsChannel reports. The firm owned 795,720 shares of the medical equipment provider’s stock after selling 2,930 shares during the quarter. Champlain Investment Partners LLC’s holdings in Masimo were worth $110,032,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the stock. Neuburgh Advisers LLC raised its holdings in Masimo by 28.8% during the first quarter. Neuburgh Advisers LLC now owns 9,376 shares of the medical equipment provider’s stock worth $1,297,000 after purchasing an additional 2,096 shares in the last quarter. Trexquant Investment LP increased its holdings in shares of Masimo by 3.8% in the first quarter. Trexquant Investment LP now owns 14,980 shares of the medical equipment provider’s stock valued at $2,071,000 after buying an additional 547 shares in the last quarter. Ascent Wealth Partners LLC increased its holdings in shares of Masimo by 8.5% in the first quarter. Ascent Wealth Partners LLC now owns 13,246 shares of the medical equipment provider’s stock valued at $1,831,000 after buying an additional 1,037 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in shares of Masimo by 62.1% in the first quarter. Neuberger Berman Group LLC now owns 190,262 shares of the medical equipment provider’s stock valued at $26,310,000 after buying an additional 72,872 shares in the last quarter. Finally, Qtron Investments LLC bought a new position in shares of Masimo in the first quarter valued at $270,000. 83.66% of the stock is currently owned by hedge funds and other institutional investors.
In other Masimo news, insider Jon Coleman sold 2,000 shares of Masimo stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $140.00, for a total transaction of $280,000.00. Following the transaction, the insider now directly owns 13,201 shares in the company, valued at approximately $1,848,140. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Ramshorst David J. Van sold 1,845 shares of Masimo stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $140.00, for a total transaction of $258,300.00. Following the transaction, the chief accounting officer now owns 1,695 shares in the company, valued at $237,300. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,695 shares of company stock worth $7,756,550. Corporate insiders own 11.50% of the company’s stock.
Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.04. Masimo had a net margin of 22.49% and a return on equity of 18.61%. The firm had revenue of $231.70 million for the quarter, compared to analysts’ expectations of $223.67 million. During the same period in the previous year, the company posted $0.75 EPS. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts forecast that Masimo Co. will post 3.12 EPS for the current fiscal year.
MASI has been the topic of several research reports. BidaskClub raised Masimo from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 14th. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price target on the stock. in a report on Tuesday, April 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $158.00 price target (up previously from $155.00) on shares of Masimo in a report on Tuesday, May 7th. UBS Group upped their price target on Masimo from $147.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Masimo in a report on Wednesday, February 27th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $154.25.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: LIBOR
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.